The effect of coenzyme Q10 on serum concentrations of adipokines and Malondialdehyde in non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206094105N8

Enrollment

Registered

2013-06-15

Start date

2013-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Other diseases of liver

Interventions

Intervention 1: One 100 milligram capsule each day for 4 weeks. Intervention 2: One capsule containing starch each day for 4 weeks.

Treatment - Drugs

Placebo

One 100 milligram capsule each day for 4 weeks

One capsule containing starch each day for 4 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Suffering from nonalcoholic fatty liver disease; Women aged 20-50 years (premenopausal) and in men 20-65 years and; Patients newly diagnosed. Exclusion criteria: Alcohol intake; Any cause of chronic liver disease other than NAFLD, such as testing positive for hepatitis B, hepatitis C and autoimmune hepatitis – Immune; Suffering from gastrointestinal disease, diabetes and rheumatoid arthritis; Presence of inherited Hemochromatosis (transferrin saturation greater than 45%) and Wilson's disease; Cholestatic liver disease; Advanced liver disease; Heart failure; Thyroid (abnormal TSH) and renal disease; History of cancer and treatment; Receiving supplements of vitamins (A,C,E), antioxidants, fiber and omega-3 within 3 weeks before baseline and during the study; Drugs such as corticosteroids, amiodarone, tamoxifen, cyclins, perhexiline, methotrexate, aspirin and hydralazine; Presence of pregnancy or lactation or menopause; Taking contraceptive drugs; Liver transplantation; Gastric bypass surgery; Performing a complete intravenous feeding; Rapid weight loss; Cut part of the intestine and gastropathy; Follow the diet and weight loss, Cachexia and taking anticoagulation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Chemerin. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: ELIZA.;Vaspin. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: ELIZA.;Malondialdehyde. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Spectrophotometry.	—

Secondary

Measure	Time frame
Food intake. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: dietary record questionnaire.;Body Mass Index. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Scales and meters.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026